Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Theravance Biopharma, Inc. (TBPH : NSDQ)

• Company Description    Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.? Number of Employees: 97

• Price / Volume Information    Yesterday's Closing Price: $18.71 Daily Weekly Monthly 20 Day Moving Average: 438,341 shares Shares Outstanding: 50.67 (millions) Market Capitalization: $948.08 (millions) Beta: 0.14 52 Week High: $20.33 52 Week Low: $7.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.05% 0.22% 12 Week 28.95% 26.87% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 901 GATEWAY BOULEVARD - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-808-6000 fax: - investor.relations@theravance.com http://www.theravance.com

• General Corporate Information    Officers Rick E Winningham - Chief Executive Officer Susannah Gray - Chairperson of the Board of Directors Aziz Sawaf - Senior Vice President and Chief Financial Officer Laurie S. Alsup - Director Eran Broshy - Director Peer Information Theravance Biopharma, Inc. (GSAC) Theravance Biopharma, Inc. (CASI) Theravance Biopharma, Inc. (ALCD.) Theravance Biopharma, Inc. (OMNN) Theravance Biopharma, Inc. (CGPI.) Theravance Biopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G8807B106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 50.67 Most Recent Split Date: (:1) Beta: 0.14 Market Capitalization: $948.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 39.81 PEG Ratio: - Price Ratios Price/Book: 4.05 Price/Cash Flow: - Price / Sales: 11.80 EPS Growth vs. Year Ago Period: 88.46% vs. Previous Quarter: -102.78% Sales Growth vs. Year Ago Period: 18.51% vs. Previous Quarter: -23.69% ROE 12/31/25 - - 09/30/25 - 12.20 06/30/25 - 6.93 ROA 12/31/25 - - 09/30/25 - 6.33 06/30/25 - 3.52 Current Ratio 12/31/25 - - 09/30/25 - 9.48 06/30/25 - 6.70 Quick Ratio 12/31/25 - - 09/30/25 - 9.48 06/30/25 - 6.70 Operating Margin 12/31/25 - - 09/30/25 - 30.34 06/30/25 - 16.88 Net Margin 12/31/25 - - 09/30/25 - 36.53 06/30/25 - 16.88 Pre-Tax Margin 12/31/25 - - 09/30/25 - 58.81 06/30/25 - 51.91 Book Value 12/31/25 - - 09/30/25 - 4.62 06/30/25 - 4.50 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©